Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.
The company cites flexibility and ease of use as its main selling points, and is partnering with IVD firms like Randox and R-Biopharm on assay development.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
Thermo Fisher will sell Synthego's synthetic guide RNA products under the Invitrogen TrueGuide brand.
The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.
PSS, which develops tools for the IVD space, will supply to Hitachi its nucleic acid isolation system, fully automated diagnostic instruments, and reagents.
Under the terms of the deal, Siemens will expand its kPCR Molecular System menu to include Fast-track's range of tests covering several medical conditions.
The program aims to assist hundreds of people diagnosed with PKU to obtain simple and affordable access to mutation analysis of the PAH gene.
The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.